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Mutations in myotubularin-related protein-2 (MTMR2) or MTMR13/set-binding factor-2 (SBF2) genes are
responsible for the severe autosomal recessive hereditary neuropathies, Charcot–Marie–Tooth disease
(CMT) types 4B1 and 4B2, both characterized by reduced nerve conduction velocities, focally folded
myelin sheaths and demyelination. MTMRs form a large family of conserved dual-specific phosphatases
with enzymatically active and inactive members. We show that homodimeric active Mtmr2 interacts with
homodimeric inactive Sbf2 in a tetrameric complex. This association dramatically increases the enzymatic
activity of the complexed Mtmr2 towards phosphatidylinositol 3-phosphate and phosphatidylinositol 3,5-
bisphosphate. Mtmr2 and Sbf2 are considerably, but not completely, co-localized in the cellular cytoplasm.
On membranes of large vesicles formed under hypo-osmotic conditions, Sbf2 favorably competes with
Mtmr2 for binding sites. Our data are consistent with a model suggesting that, at a given cellular location,
Mtmr2 phosphatase activity is highly regulated, being high in the Mtmr2/Sbf2 complex, moderate if Mtmr2
is not associated with Sbf2 or functionally blocked by competition through Sbf2 for membrane-binding sites.
INTRODUCTION
Hereditary motor and sensory neuropathies, also called
Charcot–Marie–Tooth (CMT) diseases, are among the most
common inherited neurological disorders. Clinically, they are
subdivided into two major groups on the basis of electrophysio-
logical findings in peripheral nerves. Reduced nerve conduction
velocity is observed in demyelinating neuropathies, whereas a
reduction of the signal amplitude is found in axonal neuropa-
thies (reviewed in 1). CMT4B1, an autosomal recessive
hereditary neuropathy with early onset and severe progression,
is caused by mutations in the myotubularin-related protein-2
gene (MTMR2) (2). Specific ablation of Mtmr2 in Schwann
cells mimics the human disease in transgenic mice, indicating
a glial origin of the disorder (3,4). Mutations in the related
MTMR13/set-binding factor-2 (SBF2) gene lead to CMT4B2,
a disease clinically and pathologically indistinguishable from
CMT4B1 (5,6).
The myotubularin family is a large group of protein tyrosine/
dual specificity phosphatase-like phosphatases. The founding
member, myotubularin, is the disease-causing gene in
X-linked myotubular myopathy (7). Fourteen family members
have been identified in individual mammalian genomes, and
homologs were found in all eukaryotes. Myotubularin-related
proteins (MTMRs) contain an unusually large phosphatase
domain, a pleckstrin homology-GRAM (PH-G) domain and a
coiled-coil domain. Additional motifs include FYVE
domains, pleckstrin homology (PH) domains and DENN
domains (8,9). The phosphoinositides, PI-3-P and PI-3,5-P2,
are the major enzymatic substrates of MTMRs which remove
the phosphate at the D3 position (10–12). Interestingly, not
all MTMRs are active phosphatases. Six family members bear
substitutions in catalytically essential amino acids of the phos-
phatase domain rendering them inactive. It has been speculated
that these inactive phosphatases act as substrate traps protecting
the substrate. Alternatively, they might be adaptor units for
active MTMRs (13,14).
Mtmr2 is a 73 kDa protein in its monomeric form and exists
as a dimer within cells (15). The recessive inheritance in
CMT4B1 indicates loss-of-function mutations. This function
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is likely to be the phosphatase activity because the tested
disease-associated mutations in Mtmr2 lead to loss of
phosphatase activity (11). Mtmr2 localizes to the cytosol
under steady-state conditions, but the protein re-localizes to
membranes in hypo-osmotic settings. The PH-G domain
mediates this membrane association by binding to phos-
phoinositides (15). A similar re-localization was shown for
myotubularin after EGF stimulation of COS cells (16). Sbf2
is an inactive phosphatase with a monomeric molecular
weight of 208 kDa and contains a DENN domain and a PH
domain, in addition to the basic MTMR motifs. PH domains
are involved in membrane association and usually bind to
PI-3,4-P2 and/or PI-3,4,5-P3 (17). The function of DENN
domains is less well defined. Some of the DENN domain-
containing proteins are involved in Rab and MAP kinase
signaling, pointing to a function in vesicular trafficking and
signaling processes (18).
The substrate specificity of active MTMRs suggests a func-
tion in endocytosis, sorting, and degradation of proteins,
because PI-3-P and PI-3,5-P2 are anchor sites on membranes
for effector proteins of early and late phases of the endocytic
process. PI-3-P is primarily produced by class III PI-3-kinase
and is mainly localized on early endosomes. It recruits
proteins with FYVE domains, such as EEA1 and Hrs, to this
compartment. These proteins mediate important functions
in the endocytic process (19,20). Endocytosis is blocked in
Caenorhabditis elegans MTMR mutants functionally support-
ing a crucial role of MTMRs in this process (21). PI-3,5-P2 is
generated from PI-3-P by PIKfyve. PIKfyve localizes to late
endosomes, indicating that this is the site of PI-3,5-P2 pro-
duction and function (22), although formal direct proof is
lacking because the necessary specific tools are not yet avail-
able. The role of PI-3,5-P2 in mammalian cells and the conse-
quences of the putative modulatory effects of MTMRs on this
substrate are enigmatic. Some hints have been provided by
studies in yeast, which identified Ent3p, Ent5p, Vps24p and
Svp1p as effectors of PI-3,5-P2 (23–26). These proteins
mediate various functions such as protein sorting into multi-
vesicular bodies, heat tolerance and vacuole acidification.
Thus, related processes might be regulated by mytobularins
in higher eukaryotes. From a mechanistic point of view,
dephosphorylation of PI-3,5-P2 might be critical per se, or
the product PI-5-P is the next signal in a signaling cascade.
Several interacting pairs of active and inactive MTMRs
have been described. Myotubularin binds to MTMR12
(3-PAP), MTMR7 to MTMR9 and Mtmr2 to MTMR5/sbf1
(21,27–29). At least two major lines of evidence suggest a
functionally critical interaction between Mtmr2 and Sbf2:
(i) mutations in MTMR2 and SBF2 cause identical disease
pictures in humans and (ii) MTMR5/sbf1, which interacts
with Mtmr2, shares 58% amino acid sequence identity (74%
similarity) with Sbf2. Here, we show that Mtmr2 and Sbf2
interact in vitro and in vivo in cultured Schwann cells and in
myelinated peripheral nerves, the cell type and tissue that
are the most relevant for the development of CMT4B. The
purified Mtmr2/Sbf2 complex has an apparent molecular
weight of 600 kDa, indicating that two Mtmr2 polypeptides
interact with two Sbf2 molecules, both in the form of homodi-
mers. Binding of Sbf2 to Mtmr2 strongly increases the activity
of Mtmr2 within the complex. Subcellular localization studies
suggest that Sbf2 not only acts as an adaptor and activator for
Mtmr2, but also as an independent competitive inhibitor of
Mtmr2 localization and function.
RESULTS
Interaction of Mtmr2 and Sbf2
To test the potential association of Mtmr2 and Sbf2, we per-
formed immunoprecipitation experiments with lysates from
HEK293 cells stably expressing His-tagged Mtmr2 and/or
HA-tagged Sbf2. These experiments showed that the two pro-
teins physically interact (Fig. 1A), consistent with a very
recent report (30). We also found Mtmr2/Sbf2 interactions
between the endogenously expressed proteins in lysates from
Schwann cell lines and sciatic nerve (Fig. 1B), the cell type
and tissue that are affected in CMT4B. To examine whether
Sbf2 is in a monomeric or an oligomeric state within cells,
we performed immunoprecipitation experiments from cells
that stably co-express HA- and VSV-tagged Sbf2. HA- and
VSV-tagged proteins were found to interact, indicating the
formation of Sbf2 oligomers (Fig. 1C).
To allow quantitative biochemical analysis and to gain first
structural insight, we expressed and purified the His-tagged
Mtmr2/Sbf2 complex in a baculovirus expression system that
allows simultaneous expression of multiple proteins (31). A
single NiNTA purification step, followed by gel filtration,
yielded essentially pure Mtmr2/Sbf2 complex (Fig. 2A,
inset). In addition, Mtmr2 is produced in excess in these cells
and elutes as a dimer with an apparent molecular weight of
160 kDa. The observed molecular weight for the Mtmr2/Sbf2
complex is 600 kDa, consistent with the interpretation that a
dimer of Mtmr2 (146 kDa) interacts with a dimer of Sbf2
(416 kDa) (Fig. 2A). Association of two MTMR2/Sbf2 hetero-
dimers [2  (73 þ 208 kDa)] remains a formal alternative (see
what follows). We also attempted to express Sbf2 alone with
the aim to analyze its oligomeric state. However, the protein
was largely insoluble and co-expression of Mtmr2 was required
for solubilization (data not shown).
To obtain an estimate of the overall dimensions, we ana-
lyzed the Mtmr2 dimer and the Mtmr2/Sbf2 complex by elec-
tron microscopy. The 146 kDa Mtmr2 appears as a compact
particle with a diameter of 10 nm, consistent with the
dimensions calculated from the Mtmr2 crystal structure (32;
Fig. 2B and C). The Mtmr2/Sbf2 complex is well structured
and has approximately four times the size of the MTMR2
dimers, which is in agreement with the observed apparent mol-
ecular weight values (600 and 146 kDa, respectively). Some of
the orientations of the complex suggest an X- or H-shaped
reminiscent of a 2-fold symmetry (Fig. 2D).
We have previously shown that Mtmr2 forms homodimers
via its coiled-coil domain (15). To elucidate the role of the
coiled-coil domain of Sbf2, we generated a fusion protein con-
sisting of maltose-binding protein (MBP) and the coiled-coil
domain of Sbf2, connected by a TEV protease cleavage site
in the linker. In gel filtration, the MBP–Sbf2cc fusion
protein eluted at an apparent molecular weight of 110 kDa,
indicating dimerization of the 58 kDa fusion protein
(Fig. 3A). To confirm that the dimerization is mediated by
the Sbf2 coiled-coil domain, we cleaved the MBP–Sbf2cc
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fusion protein with TEV protease and analyzed the products
by gel filtration. After cleavage, MBP eluted as a monomer
(apparent molecular weight of 43 kDa). The Sbf2 coiled-coil
domain (15 kDa) eluted at 30 kDa, consistent with dimeriza-
tion (Fig. 3A). Thus, Sbf2 forms homodimers mediated by its
coiled-coil domain.
It is intriguing to speculate how the coiled coils of Mtmr2
and Sbf2 are involved in tetramer formation (Fig. 3B). To
address this issue, we used cell lines expressing HA-tagged
Sbf2 and His-tagged Mtmr2. Although Mtmr2 and Mtmr2-
C417S (the C417S mutation inactivates the phosphatase
domain) interact with Sbf2, Mtmr2-P589X (coiled coil
deleted) does not bind to Sbf2 (Fig. 3C). Conversely, when
the coiled coil of Sbf2 was deleted, we found no interaction
with Mtmr2 (data not shown). Hence, the coiled-coil
domains are necessary to form two homodimers which then
assemble independently of the coiled coils to a tetramer, or
the interaction of Sbf2 and Mtmr2 occurs via a four-stranded
coiled coil. Alternatively, two Mtmr2/Sbf2 heterodimers form
via the coiled coils and assemble independently of the coiled
coils to a tetramer (Fig. 3B). To examine these possibilities,
we mixed MBP-Sbf2cc with a fusion protein of thioredoxin
and the Mtmr2 coiled coil (Trx–Mtmr2cc). Trx–Mtmr2cc
forms a stable dimer (15). An equimolar mixture of MBP–
Sbf2cc and Trx–Mtmr2cc was analyzed by gel filtration
(Fig. 3D). The two proteins eluted separately as homodimers
without signs of tetramerization or heterodimerization. Alter-
ing the molecular ratios (2:1, 10:1 and 1:10) or incubating
the proteins at 4 or 258C also yielded no complexes of
higher molecular weight. Partial thermal denaturation of the
mixture at 508C, followed by co-renaturation overnight, exclu-
sively yielded homodimers. Finally, we incubated the MBP–
Sbf2cc and Trx–Mtmr2cc mixture at 608C, causing partial
precipitation of MBP–sbf2cc. All remaining soluble MBP–
Sbf2cc and all Trx–Mtmr2cc eluted after renaturation as
homodimers. Thus, the homomeric interactions are extremely
stable, excluding heterodimerization as well as tetramerization
of the coiled-coil domains. Furthermore, a mixture of Mtmr2
dimer produced in insect cells and MBP–Sbf2cc dimer was
analyzed by gel filtration, but no heterologous complex for-
mation was observed (data not shown). We conclude that
the coiled-coil domains exhibit their function in Mtmr2/Sbf2
tetramer formation indirectly by mediating homodimerization
of Mtmr2 and Sbf2 (Fig. 3B, top).
Phosphatase activity
We have shown previously that bacterial GST-tagged and
His-tagged Mtmr2 dephosphorylates PI-3-P and PI-3,5-P2 at
position D3 of the inositol ring. Other reports indicate that
Figure 1. Sbf2 interacts with Mtmr2 and oligomerizes. (A) Immunoprecipitation from 293-FlpIn cells stably expressing His-tagged Mtmr2 and HA-tagged Sbf2
(panel 1). HA-tagged Sbf2 (asterisk) co-immunoprecipitates with His-tagged Mtmr2 (lane 1) and vice versa (lane 2). Immunoprecipitation from cells expressing
His-tagged Mtmr2 (panel 2), HA-tagged Sbf2 (panel 3) and FlpIn293 (panel 4) cells were performed as controls. (B) Immunoprecipitation with monoclonal anti-
Mtmr2 antibody and detection by western blotting with polyclonal rabbit anti-Mtmr2 (upper panel) and anti-Sbf2 (lower panel) antibodies. Mtmr2 is detected in
sciatic nerve and in various Schwann cell lines. In sciatic nerve extracts, a degradation product of 55 kDa was observed, besides the full-length form. Sbf2 is
co-precipitated from sciatic nerve and Schwann cell lysates. Control: purified Mtmr2/Sbf2 complex (Fig. 2). Note that the levels cannot be quantitatively com-
pared because less input lysate was used for the sciatic nerve. (C) Immunoprecipitation from 293-FlpIn cells stably expressing HA-Sbf2 (lane 1 in both panels)
and HA- and VSV-tagged Sbf2 (lane 2). VSV-tagged Sbf2 co-immunoprecipitates with HA-tagged Sbf2 (left panel) and vice versa (right panel), indicating that
Sbf2 exists within cells as an oligomer.
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probably all active MTMRs show this substrate specificity
(10–12). Kim et al. (29) demonstrated, using separately puri-
fied proteins in a mixture that probably also contained uncom-
plexed Mtmr2 dimers, that the inactive phosphatase MTMR5/
sbf1 increases the catalytic activity of Mtmr2. Our expression
system and purification procedure yielded Mtmr2 dimer and
Mtmr2/Sbf2 complex separately, providing us with the oppor-
tunity to measure the catalytic properties of pure Mtmr2/Sbf2
complex and pure Mtmr2 dimer independently. We found that
both, Mtmr2 and Mtmr2/Sbf2 complex, use PI-3-P and PI-
3,5-P2 as substrates (Fig. 4). The activity towards PI-4-P, PI-
5-P, PI-3,4-P2, PI-4,5-P2 and PI-3,4,5-P3 was at background
level (data not shown). The catalytic activity of Mtmr2
alone towards PI-3,5-P2 was similar to the previously
described activity (11). In contrast, the activity of the
Mtmr2/Sbf2 complex is more than 25-fold increased. Simi-
larly, the activity towards PI-3-P increases 10-fold upon
Mtmr2/Sbf2 complex formation. The activity of the Mtmr2/
Sbf2 complex towards PI-3,5-P2 is approximately two times
higher than towards PI-3-P (Fig. 4). Thus, the association of
the inactive phosphatase Sbf2 with Mtmr2 is of paramount
importance for the regulation of the specific Mtmr2 phospha-
tase activities towards PI-3,5-P2 and PI-3-P.
Subcellular localization of Mtmr2 and Sbf2
The subcellular localization of MTMRs and its dynamics are
of special interest in respect to the function of MTMRs.
Mtmr2 localizes to the cytosol under steady-state conditions.
Under hypo-osmotic conditions or after EGF stimulation of
COS cells, Mtmr2 can bind as a dimer to membranes of
late endosomes via its PH-G domain (15,16). It has been
postulated that inactive mytobularin phosphatases regulate
PI-3-phosphatase activity by targeting the active partner to
the substrate (27,29). We analyzed the subcellular localization
of Mtmr2 and Sbf2 in double-transfected COS cells in com-
parison with markers for vesicles of the endocytic pathway
(Fig. 5). In Mtmr2/Sbf2 double-expressing cells, Mtmr2 is dif-
fusely distributed in the cytosol as has been described for cells
expressing Mtmr2 alone (15). Sbf2 is also present dispersed in
the cytosol but the staining appeared more granular, compar-
able to cells expressing Sbf2 alone (data not shown).
Mtmr2/Sbf2 stainings overlap considerably in line with the
observed complex formation. No appreciable co-localization
of Mtmr2 or Sbf2 with markers of early endosomes (EEA1),
late endosomes (LBPA) or lysosomes (LAMP-2) was
observed. Thus, despite the uneven distribution of Mtmr2
and, in particular, Sbf2 within the cells, these proteins are
not strongly associated with these vesicles under resting con-
ditions (Fig. 5). Under hypo-osmotic conditions, Sbf2 is redis-
tributed to membranes of vacuoles formed in this setting. In
contrast, no Mtmr2 staining was usually found on these vacu-
oles (Fig. 6A). Only cells with low Sbf2 expression show a co-
staining of Mtmr2 and Sbf2 (Fig. 6B). This is surprising
because cells on the same plate that only express Mtmr2
exhibit Mtmr2 vacuole membrane staining consistent with
Figure 2. The Mtmr2/Sbf2 complex. (A) His-tagged Mtmr2 and CBP-tagged Sbf2 were expressed in sf21 cells, purified with NiNTA chromatography and ana-
lyzed by gel filtration. Peak I elutes with the void volume and does not contain proteins (large inset, lane 3). Peak II contains Mtmr2 and Sbf2 and elutes with an
approximate molecular weight of 600 kDa, consistent with a (Mtmr2)2/(Sbf2)2 complex (calculated molecular weight: 570 kDa). Peak III elutes at an apparent
molecular weight of 160 kDa and contains Mtmr2 homodimer, which is produced in excess in sf21 cells (small inset). (B) Crystal structure of the Mtmr2 dimer
for size comparison (32). (C–D) Electron micrographs of negatively stained Mtmr2 and Mtmr2/Sbf2 complex. (C) Electron microscopic analysis of Mtmr2.
Round particles with an approximate diameter of 10 nm were observed (arrows). (D) Electron micrographs of the Sbf2–Mtmr2 complex. X- or H-shaped par-
ticles with an 4-fold larger size were seen (arrows). Beneath, four selected raw images with representative orientations are shown. Scale bars: 10 nm in B;
50 nm for overview pictures in C and D; 10 nm for magnifications in C and D.
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earlier observations (15) (Fig. 6D). We conclude that Sbf2
binds with considerably higher affinity than Mtmr2 to
membranes of these vacuoles, thereby competing for Mtmr2-
binding sites. This higher affinity can be mediated by the inter-
action of Sbf2 with membrane-binding proteins or membrane
lipids (see what follows).
Lipid-binding properties of Sbf2
Sbf2 contains two putative lipid-binding domains, a PH-G
domain and a classical PH domain. The PH-G domain was
initially defined on the basis of primary sequence data, and
the determination of the three-dimensional structure of
Figure 3. Function of the coiled coils of Sbf2 and Mtmr2. (A) Analysis of the coiled-coil region of Sbf2 fused to MBP with a TEV cleavage site in between
(MBP–Sbf2cc, 58 kDa). Size exclusion chromatography revealed a molecular weight of 110 kDa for the fusion protein, indicating that the coiled coil mediates
dimerization (SDS–PAGE section on top). After cleavage with TEV protease between MBP (43 kDa) and the coiled coil (15 kDa), MBP elutes as a monomer
and the coiled coil as a dimer (dotted line, SDS–PAGE analysis section at the bottom). (B) Putative forms of interactions between MTMR2 and Sbf2. (Top)
Assembly of two homodimers. This model is in line with our data. (Middle) Two homodimers which form a four-stranded coiled coil. (Bottom) Two hetero-
dimers forming the tetramer. (C) Immunoprecipitation experiments from FlpIn293 cells stably expressing HA-Sbf2 and His-Mtmr2 (lane 1), HA-Sbf2 and His-
Mtmr2 C417S (w/o phosphatase activity, lane 2) and HA-Sbf2 and His-Mtmr2 P589X (w/o coiled coil, lane 3). Deletion of the coiled coil in Mtmr2 prevents the
interaction with Sbf2. (D) Mixing of MBP–Sbf2cc (58 kDa) and the coiled coil of Mtmr2 fused to thioredoxin (Trx–Mtmr2cc, 20 kDa), both homodimers,
yielded a mixture of the homodimers (solid line). Neither a 78 kDa peak indicative of a heterodimer nor a 156 kDa peak for a tetrameric assembly was observed
(straight line, SDS–PAGE section at the bottom). The elution profiles of the fusion proteins applied separately are shown as dotted lines.
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Mtmr2 revealed a PH fold (32,33). This PH-G domain binds to
phosphoinositides with broad specificity (15,16). We used a
protein–lipid overlay assay to determine the lipid-binding
properties of the PH-G domain of Sbf2 fused to an N-terminal
GST tag (34) and found that the PH-G domain of Sbf2 binds to
PI-4-P, PI-5-P, PI-3,5-P and PI-3,4,5-P3 (Fig. 7A). This result
is comparable to the findings with the PH-G domain of Mtmr2,
indicating that this broad specificity might be common to PH-G
domains, potentially defining a subclass within the large PH
domain family. Interestingly, the PH domain at the C-terminus
of Sbf2 shows specific binding only to PI-3,4,5-P3 (Fig. 7B).
DISCUSSION
Mutations in MTMR2 and SBF2 lead to the clinically indistin-
guishable peripheral neuropathies, CMT4B1 and CMT4B2,
respectively. This genetic hint and known associations of
active and inactive MTMRs led us to investigate whether and
how the active phosphatase Mtmr2 and the inactive phospha-
tase Sbf2 interact. We show that Mtmr2 and Sbf2 form a tetra-
meric complex composed of two homodimers. Association of
Sbf2 with Mtmr2 strongly increases the enzymatic activity of
the latter. The interaction between Mtmr2 and Sbf2 is tightly
regulated, indicating that the individual proteins and the
Mtmr2/Sbf2 complex play multiple roles within the cell.
The Mtmr2/Sbf2 complex
MTMRs form a large family of lipid phosphatases including
both active and inactive members. Immunoprecipitation
from transfected cells had revealed previously that some
active and inactive members interact (27–29). Our initial
experiments with cellular and tissue lysates showed that
Mtmr2 and Sbf2 associate with each other. Thus, we produced
and purified the Mtmr2/Sbf2 complex for biochemical analysis
using MultiBac, a recently described baculovirus-based
system for multi-protein applications (31). The expression
levels of both Mtmr2 and Sbf2 were high when compared
with previous experience with Mtmr2 expression in E. coli,
demonstrating that eukaryotic systems offer significant advan-
tages for efficient expression of MTMRs. We found that Sbf2
expressed alone is largely insoluble, suggesting that appropri-
ate partners such as Mtmr2 are required for stabilization
within cells. Co-expressed Mtmr2 and Sbf2 were isolated as
a high molecular weight complex of 600 kDa, most consist-
ent with an association of an Mtmr2 dimer with an Sbf2 dimer
to form a (Mtmr2)2/(Sbf2)2 complex. The existence of tetra-
mers is further supported by electron microscopic analysis
of the Mtmr2/Sbf2 complex, indicating an 4-fold larger
size as compared to the Mtmr2 dimer. The complex appears
as X- or H-shaped particle consistent with speculations
that the arms of the particle may be the N-terminal DENN
and the C-terminal PH domains of Sbf2 because these are
likely to form independent domains.
We assessed in two ways the function of the coiled-coil
domains in Mtmr2 and Sbf2 in complex formation. Immuno-
precipitation experiments revealed that deletion of the
C-terminus containing the coiled coil of Mtmr2 or of Sbf2
abolished the interactions consistent with a recent publication
(30). We then mixed the individual coiled coils of Mtmr2 and
Sbf2 fused to thioredoxin and MBP, respectively, and found
no indication of formation of heterodimeric or heterotetra-
meric complexes. Both coiled-coil proteins remained in or
reformed their homodimeric state even after thermal unfolding
followed by refolding. We conclude that the coiled-coil
domains are not directly mediating the interaction between
Mtmr2 and Sbf2. However, they are indirectly essential to
mediate stable homodimerization (Fig. 3B, top). The inter-
action of Mtmr2 and Sbf2 in the complex must involve
further domains, besides the coiled coils. In analogy, this
might also hold true for other interacting pairs of active and
inactive members of the myotubularin protein family. An
attractive hypothesis would be that the phosphatase domain
of Mtmr2 is involved in the formation of the Mtmr2/Sbf2
complex because the phosphatase activity is significantly
upregulated upon complex formation.
Phosphatase activity and subcellular localization
Binding of Sbf2 to Mtmr2 increases the activity towards PI-
3-P 10-fold and towards PI-3,5-P2 25-fold. This implies
that complex formation drastically affects Mtmr2 phosphatase
activity and causes a slight shift in substrate specificity.
Understanding the biological significance of these findings is
crucially important for the elucidation of the cellular roles of
Mtmr2 and Sbf2. Mechanistic hints to this end were revealed
by subcellular localization studies. In cells expressing Mtmr2
or Sbf2 alone, both proteins localize to the cytoplasm. Under
hypo-osmotic conditions, vacuoles formed and Mtmr2 or Sbf2
accumulated at the membranes of these vesicles. A different
picture emerged when Mtmr2 and Sbf2 were expressed in
the same cell. We found a broad but incomplete overlap of
Mtmr2 and Sbf2 in the cytoplasm. Hypo-osmotic conditions
were applied, Sbf2 when bound to membranes of the formed
vacuoles, whereas Mtmr2 remained in the cytoplasm. This
intriguing preference for Sbf2 binding may reflect a higher
affinity of the Sbf2 PH-G domain to phosphoinositides when
Figure 4. Phosphatase activity of Mtmr2 and Mtmr2/Sbf2 complex. The phos-
phatase activity was measured in a malachite green-based assay with di-C8
phosphoinositides as substrates. Only PI-3-P and PI-3,5-P2 were dephosphory-
lated by Mtmr2 and the Mtmr2/Sbf2 complex. Association of Mtmr2 with
Sbf2 strongly increases phosphatase activity. Please note that the activity of
Mtmr2 expressed in a eurkaryotic system towards the substrates is similar to
the previously described values for Mtmr2 expressed in a prokaryotic system.
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compared with the Mtmr2 PH-G domain. Alternatively, other
domains of the proteins or additional unknown factors might
be involved. The PH domain of Sbf2 is an attractive candidate
to play a role in this context, but this requires experimental
confirmation. The distinct localizations of Mtmr2, Sbf2 and
the Mtmr2/Sbf2 complex suggest an intriguing multi-level
model for the regulation of Mtmr2 phosphatase activity. (i)
The activity is maximal in defined regions of the cytoplasm
where the Mtmr2/Sbf2 complex is located. (ii) Moderate
activity is associated with the Mtmr2 dimer in the cytoplasm,
or if the protein is bound to particular membranes in the
absence of Sbf2. (iii) Mtmr2 phosphatase activity can be
blocked at particular membranes owing to competition with
Sbf2 for binding sites. Under resting conditions, the Mtmr2/
Sbf2 complex likely degrades PI-3,5-P2 (and/or PI-3-P) with
maximal efficiency, which may explain the low cellular
levels of PI-3,5-P2. Complexes between active and inactive
MTMRs might downregulate PI-3,5-P2 levels in mechanisti-
cally similar ways in many different cell types, as MTMRs
are ubiquitously expressed.
PI-3,5-P2 levels transiently rise upon stimulation of cells
with hypo-osmotic shock, EGF or interleukin-2 (16,35,36).
Such an effect can be achieved either by transient production
of the substrate or by protecting it from degradation. A protec-
tive function was initially postulated for the inactive MTMR5/
sbf1 in the context of phosphorylated proteins (13). Our results
suggest that inactive MTMR phosphatases have functions as
(i) adaptors for the correct localization of active MTMRs,
(ii) protectors of PI-3,5-P2 and (iii) regulators of phosphatase
activity of the active MTMR partners.
Implications for human disease
The correct function of MTMRs is crucial for human health.
Mutations in three of the 14 family members cause hereditary
human diseases. Mutations in myotubularin lead to X-linked
myotubular myopathy, and mutations in either MTMR2 or
SBF2 lead to the severe peripheral neuropathies, CMT 4B1
and 4B2, respectively (3,5–7). MTMR2 is an active phospha-
tase which dephosphorylates PI-3-P and PI-3,5-P2 and loss
of catalytic activity correlates with CMT4B1 (11). Sbf2 is
an inactive phosphatase of the myotubularin family and all
disease-associated mutations known to date lead to shortened
or truncated proteins, also implicating loss-of-function.
Figure 5. Subcellular localization of Mtmr2 and Sbf2. COS cells were co-transfected with Sbf2 and EGFP-Mtmr2 expression constructs and stained with
markers for early endosomes (EEA1), late endosomes (LBPA) and lysosomes (LAMP-2). In double-expressing cells, both Mtmr2 and Sbf2 are diffusely
distributed in the cytosol and do not co-localize appreciably with these vesicular markers under resting conditions. Scale bar: 20 mm.
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Experiments in transgenic mice have shown that the Schwann
cell-specific function of Mtmr2 is critical for the disease (3,4).
We demonstrate that Mtmr2 and Sbf2 are interaction partners
in Schwann cells in vitro and in vivo. This interaction is most
likely the molecular basis for the identical phenotypes caused
by mutations in Mtmr2 and Sbf2, indicating that these proteins
act in concert in a bottleneck of an important pathway. Our
data suggest that loss of Mtmr2/Sbf2 complex function, invol-
ving lack of maximal phosphatase activity, is responsible for
the human disease. However, more subtle alterations in cellular
physiology, as indicated by the complex interplay between
Mtrm2 and Sbf2, remain to be considered as contributing factors.
Future aspects
Our ability to reconstitute the Mtmr2/Sbf2 complex recombi-
nantly using baculovirus expression allows stochiometric,
enzymatic and structural analysis. The system is expandable,
and additional potential binding proteins can be added in the
co-expression experiments. So far, MTMR5/sbf1, neurofila-
ment light chain protein and SAP97 have been identified as
additional binding partners of Mtmr2 (3,29,37). Future
studies will reveal how these proteins bind to the Mtmr2/
Sbf2 complex, whether they bind together or compete with
each another and how they influence catalytic activity and
complex localization.
MATERIALS AND METHODS
Cloning and antibodies
The mouse Sbf2 cDNA was obtained by assembling RT–PCR
fragments generated from mouse brain and sciatic nerve RNA.
The resulting sequence fitted with the consensus sequence of
the available EST clones. Mutations and tags were introduced
using a PCR-based strategy with Taq Plus Precision Polymerase
Figure 6. Subcellular localization of Mtmr2 and Sbf2 under hypo-osmotic conditions. COS cells were co-transfected with Sbf2 and His-Mtmr2 expression con-
structs. All pictures are from the same plate. (A) In cells expressing high levels of Sbf2, Sbf2 preferentially binds to the membrane of vesicles. (B) In cells with
moderate Sbf2 expression, both Mtmr2 and Sbf2 bind to vesicles. (C) Quantification of labeled vesicle in double-expressing cells. ‘Sbf2-positive’ indicates per-
centage of vesicles labeled only for Sbf2, ‘Mtmr2-positive’ denotes percentage of vesicles labeled for Mtmr2 only and ‘Sbf2/Mtmr2-positive’ stands for per-
centage of double-labeled vesicles. Three times 100 vesicles in double-expressing cells from three independent experiments have been counted. (D) In cells
which only expresses Mtmr2, Mtmr2 localizes to the vesicular membrane, as previously described in single-transfected cells (15). In single Sbf2-transfected
cells under hypo-osmotic conditions, Sbf2 is also localized on the newly formed vesicles (data not shown).
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(Stratagene). All constructs were verified by sequencing. The
polyclonal anti-Sbf2 antiserum was obtained by immunizing
rabbits with the peptide N-CKNKLLRASAPGDWES-C
coupled to keyhole limpet hemocyanine (Pineda, Berlin). Pro-
duction and characterization of monoclonal Mtmr2 antibodies
will be described elsewhere.
Cell culture
For eukaryotic expression, the cDNA was cloned in the
pcDNA3.1 zeo(þ) and the pcDNA5/FRT vector. COS cells
were transfected with Fugene6 (Roche) or Superfect
(Qiagen) according to the manufacturer’s recommendations.
Stably expressing HEK293 FlpIn cells were produced by co-
transfection of a pcDNA5/FRT vector with the Flp recombi-
nase expression plasmid pOG44 followed by selection with
hygromycin (FlpIn system, Invitrogen). Cells stably expres-
sing two different proteins were produced by transfection
of the described FlpIn cells with a pcDNA3.1 zeo(þ) vector
followed by selection with zeocin and hygromycin.
Immunoprecipitation
Approximately 400 cm2 of stably transfected HEK293 FlpIn
cells were removed from the plates with Lysis Buffer A
(0.5% Triton X100, 100 mM NaCl, 50 mM Tris–HCl, pH
7.5). Cells were sonicated and cell debris removed by centrifu-
gation. The supernatant was incubated for 2 h with 10 ml
protein A Sepharose (Pharmacia) carrying either 1 mg mouse
anti-RGSHis (Qiagen), 1 mg mouse anti-VSV (P5D4, Roche)
or 0.5 mg rat anti-HA (3F10, Roche) antibody. The beads
were washed three times with Lysis Buffer A. Bound proteins
were separated on an 8% SDS–PAGE and identified
by western blotting with anti-RGSHis, anti-VSV and anti-HA
antibodies. As secondary antibodies, alkaline phosphatase-
coupled goat anti-mouse and horse radish peroxidase-coupled
rabbit anti-rat were used, followed by chemiluminescence
detection.
Coiled-coil fusion constructs
The following primers were used to amplify the coding
sequence for a TEV-site, the 125 amino acid long region
between the phosphatase and PH domain of Sbf2 containing
the coiled coil, and a C-terminal His-Tag: 50-GATC
GAATTC GAA AAC CTG TAT TTT CAG GGG GGA
GGA GCT GGG CCC CAG-30 and 50-GATC TCTAGA
TCA ATG GTG ATG GTG ATG GTG GTT CTT GGA
TGT GTA CTG-30. The fragment was cloned into the
pMALc vector (NEB). The protein was expressed in E. coli
Rosetta cells and purified via Amylose (NEB) and NiNTA
(Qiagen) resin according to manufacturers’ recommendations.
The production of His-tagged thioredoxin fused to the coiled
coil of Mtmr2 is described elsewhere (15).
Baculovirus expression and purification of Mtmr2
and Sbf2
The construct for the expression of His-tagged Mtmr2 under
the control of the p10 promoter was generated by inserting
an EcoRI (blunt ended)/SalI fragment from the pQE30-
Mtmr2 vector (15) into SmaI/XhoI cut pFBDM shuttle
vector (31) resulting in pFBDM-Mtmr2. For dual expression
of Mtmr2 and Sbf2, the cDNA for a calmodulin-binding
protein (CBP)-tagged Sbf2 was inserted into MCS1 of
pFBDM-Mtmr2 under the control of the polyhedrin promoter
resulting in the dual expression vector pFBDM-Sbf2–Mtmr2.
For expression of Sbf2 alone, the Mtmr2 expression cassette
was excised from this dual vector with KpnI and BssHII.
His-tagged Mtmr2 and CBP-tagged Sbf2 were co-expressed
in sf21 cells as described (31). After centrifugation, cells
were lysed by sonification in Lysis Buffer B (50 mM Tris–
HCl, 100 mM NaCl, 0.5% Triton X100, 10 mM imidazole,
2 mM PMSF, Sigma protease inhibitor cocktail, pH 8.5). The
cleared lysate was applied to an NiNTA column, washed
and eluted with Lysis Buffer B with increasing concentrations
of imidazole. The eluted complex contained Mtmr2 and Sbf2,
as confirmed by western blotting with mouse anti-His and
rabbit anti-Sbf2 antibodies (data not shown). In a complemen-
tary experiment, the lysate was bound to calmodulin-affinity
resin, washed and then eluted with 50 mM Tris–HCl, 2 mM
EGTA, 1M NaCl, 10 mM b-mercaptoethanol, pH 8.0.
Western blotting also confirmed that the complex contained
both Mtmr2 and Sbf2 (data not shown). The eluate of the
NiNTA column was loaded on a Superdex S200 HR gel fil-
tration column with 50 mM Tris–HCl, 100 mM NaCl, 0.01%
Tween, pH 8.0, as elution buffer.
Negative-stain electron microscopy
Mtmr2/Sbf2 complex was purified from sf21 cells by NiNTA
and calmodulin-affinity resin chromatography. Pure Mtmr2
dimer was obtained by NiNTA chromatography followed by
gel filtration. Mtmr2 samples at 10 mg/ml and Sbf2-Mtmr2
samples at 12 mg/ml were adsorbed to glow-discharged
carbon grids for 30 s, followed by washing with two drops
of deionized water and staining with two drops of 1% uranyl
acetate. Images were taken with a 2 k CCD camera at a mag-
nification of 53 000 and a defocus of 2 mM, using the low-
dose procedure with a Philips TecnaiF20 electron microscope
operated at 200 kV.
Figure 7. Protein–lipid overlay assay with the GST-tagged PH-G domain and
the PH domain of Sbf2. (A) Serial dilutions of spotted phospholipids (100–
3 pmol in 2-fold dilution steps from left to right) were incubated with the
PH-G domain of Sbf2. A broad binding specificity is observed. (B) The PH
domain of Sbf2 binds preferentially to PI-3,4,5-P3.
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Phosphatase activity
Purified Mtmr2 dimer and Mtmr2/Sbf2 complex from sf21
cells were used for the activity assays. As substrates, diC8
phosphoinositides from Echelon were used (Malachite Green
Phosphatase Assay Kit). Assays were performed at 308C in
a buffer containing 25 mM Tris–HCl pH 7.5, 5% glycerol,
2 mM DTT and 50 mM phosphoinositide. Aliquots were
taken after 0.5–32 min and the reaction was stopped by
adding N-ethylmaleimide to a final concentration of 7 mM
and incubating at 958C. Assays were performed with all
seven phosphoinositides and their solubilization was tested by
dephosphorylation with alkaline phosphatase in independent
experiments.
Immunostainings
Cells were transfected as described previously and fixed 24 h
after transfection with 2 or 0.5% paraformaldehyde in PBS.
Hypo-osmotic conditions were applied as previously described
(15). Cells were blocked in blocking buffer (10% FCS/0.05%
Saponin/PBS) for 30 min prior to incubation with antibodies.
Antibodies were diluted in blocking buffer as follows:
mouse anti-EEA1 (1:300; BD Transduction Laboratories),
mouse anti-LBPA (1:100; kindly provided by J. Gruenberg,
Geneva), mouse anti-LAMP-2 (H4B4; 1:10; Developmental
Studies Hybridoma Bank); mouse anti-RGSHis6 (1:200;
Qiagen), rabbit anti-Sbf2 (1:1000). Appropriate Cy2, Cy3,
Cy5 and ALEXA488 secondary antibodies were used for
visualization.
Protein–lipid overlay assay
The predicted phosphoinositide-binding domains of Sbf2 were
expressed in E. coli as fusion proteins with N-terminal GST
tags. For the PH-G domain, the coding region of amino
acids 864–1003 was amplified with Taq Plus Precision Poly-
merase (Stratagene) and cloned into the BamHI/EcoRI cut
pGEX-2T vector (Pharmacia). For the C-terminal PH
domain, the coding region of amino acids 1719–1847 was
cloned into the EcoRI cut pGEX-2T vector. The proteins
were expressed and purified according to manufacturers’ rec-
ommendations (Pharmacia). The protein–lipid overlay assay
was performed with membranes from Echelon Biosciences
(Salt Lake City), as previously described (15).
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